Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.
Finding how leukemia cells hide from immune attacks opens new ways to restore the body's natural cancer-fighting defenses.
Researchers discovered that AML cells coat themselves with sialylated CD43, forming a sugar-based shield that prevents immune cells from attacking. Disrupting this barrier restored immune-mediated killing in laboratory and animal models, suggesting a new immunotherapy target for AML.
What the study was
- Study design
- Preclinical with patient-derived samples (CRISPR screens, in vivo models, patient AML samples)
- Population
- AML patients and preclinical models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Science
Why it surfaced
First identification of sialylated CD43 as a glyco-immune checkpoint in AML, published in Science with accompanying editorial commentary. Establishes a novel therapeutic target class for AML immunotherapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.